John Parkinson

Stephanie Spivack, MD, talks about the diverse educational experiences afforded to fellows during their time at Temple University as well as the devoted clinical care that serves the local community.

César de la Fuente, PhD, provides insights on the promising work of his lab as they accelerate the speed of finding new antimicrobial molecules.

This comes after the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) made the recommendation to remove the vaccine preservative.

In the largest world study, there was a 98% reduction in hospitalizations of babies who received the RSV vaccine compared with those who did not receive the RSV vaccine.

In the second installment of our Media Day interview, Temple University Hospital’s Rafik Samuel, MD, talks about what he has experienced as a clinician seeing patients with HIV before there were treatments available as well as his approach with fellows in teaching them about this disease.

Rafik Samuel, MD, chief of the Section of Infectious Disease at Temple University Hospital and professor of medicine at Lewis Katz School of Medicine at Temple University, talks about its history and the uniqueness of its fellowship program.

First author Jacek Skarbinski, MD, offers insights on new data published last week showing how this population can benefit from continued vaccination.

Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP) talks about how his team developed a test to identify fungi, and how they utilize it to diagnose, make treatment adjustments, and rule out hospital acquired infections.

Margie Lee, DVM, MS, PhD, wants young researchers and providers to know that despite the current environment, this is not the first time science has had to deal with a challenges to research and funding.

Cases and deaths in the state are down from the 2 previous years. Here are some clinical considerations, treatment options, and prevention strategies in relation to these infections.

In the second installment of our conversation with Jeremy Faust, MD, he addresses the uncertainty surrounding guidance and where to turn for information.

A large study looked at booster uptake and effectiveness among US adults who received chemotherapy or immunotherapy.

Jeremy Faust, MD, discusses what he and other providers are dealing with in the face of conflicting guidance and actions from the federal agencies.

TAXIS Pharmaceuticals Chief Scientific Officer Ajit Parhi, PhD, discusses dihydrofolate reductase inhibitors as a novel approach to combat resistant Neisseria gonorrhoeae.

The company said it expects to have its updated mRNA-1273 (Spikevax) vaccine available for these eligible populations in the US for the next respiratory virus season.

This investigational two-drug regimen for treatment of adults with virologically suppressed HIV was given a Prescription Drug User Fee Act (PDUFA) date of April 28, 2026.

Sara Embry discusses her experience with the infection while pregnant and as a mother to young children as well as finding the Peggy Lillis Foundation to help her cope with the infection and subsequently work as a peer support volunteer for the organization.

Results from Invivyd’s pemivibart (Pemgarda) phase 3 trial show it had a significant PrEP effect during the 6-month on-drug period for both immunocompromised and immunocompetent populations.

Johns Hopkins is offering its Pamela Tucker transplant and oncology infectious diseases course. Its director, Shmuel Shoham, MD, offers more information about this continuing education opportunity.

Paul Feuerstadt, MD, FACG, AGAF, offers a glimpse of patients dealing with this and insights on improving patients’ quality of life, post-treatment with fecal microbiota, live-jslm (Rebyota [RBL]).

The philanthropic organization plans to provide the gift over the next 5 years, and is in contrast with what is happening with US vaccine funding to the organization as well as the country's changing immunization policies.

Marketed as Orlynvah, oral sulopenem from Iterum Therapeutics was FDA approved last fall for uncomplicated urinary tract infections and has shown efficacy against infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis.

Rodney Rohde, PhD, SM(ASCP), SVCM, MBCM, FACSc, discusses the ongoing concerns about the federal government’s hold on funding for research and the potential chilling effect that it may have on laboratory professionals and deciding on careers, especially in areas such as public health. He also talks about locating and engaging in potential alternative resources for research funding.

At ASM Microbe 2025, Meghan Starolis, PhD, discusses her presentation on antiviral testing including the advantages and limitations to genotypic and phenotypic testing and looking at how this can affect the immunocompromised population.

American Society for Microbiology (ASM) CEO Stefano Bertuzzi, PhD, MPH, talks about ASM's comprehensive scientific program, the networking opportunities at the meeting, and the unique format ASM plans to roll out for the 2026 conference.

In a wide-ranging interview, Susan Weiss, PhD, talks about winning the ASM Lifetime Achievement award, her work on coronaviruses, and her concerns around federal government funding and how it may shake up and limit basic science research.

At the ASM Microbe conference, Mike Bromley, PhD, offers some insights on the importance of a One Health approach addressing the growing antifungal resistance to azoles and Aspergillus fumigatus because of the connection between crop spraying and the rise of resistance.

Jatin Vyas, PhD, MD, offers some insights into the economics of development, the biology of fungal species, and the difficulties behind creating new antifungal molecules.

The antiviral, glecaprevir/pibrentasvir (Mavyet), is the first and only oral 8-week pangenotypic treatment approved for people with acute or chronic hepatitis C. The approval supports global clinical guidelines to advance testing and treatment of HCV regardless of chronicity and supports public health goals for disease elimination.

The federal agency approved the company’s mRNA-1345 (mRESVIA) vaccine for people who are between the ages of 18 to 59 years.